PDCD1 and neoplasm: Irrespective of the underlying mechanism, our results emphasize the importance of intact tumor MHC-I expression for anti-PD-1 monotherapy response and indicate that combination immunotherapy may provide clinical benefit irrespective of tumor MHC expression and immune contexture.